Cathelicidin antibody (AA 115-121)

Catalog No. ABIN2666321

This anti-Cathelicidin antibody is a Mouse Monoclonal antibody detecting Cathelicidin in FACS. Suitable for Human.

Quick Overview for Cathelicidin antibody (AA 115-121) (ABIN2666321)

Target: Cathelicidin (CAMP) (Cathelicidin Antimicrobial Peptide (CAMP))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Cathelicidin antibody is un-conjugated

Application: Flow Cytometry (FACS)

Clone: H7

Product Details anti-Cathelicidin Antibody

Binding Specificity: AA 115-121

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: phosphate-buffered solution, pH 7.2, 0.09 % Sodium azide.

Storage: 4 °C

Storage Comment: Upon receipt, store undiluted between 2°C and 8°C.

Target Details for Cathelicidin

Target: Cathelicidin (CAMP) (Cathelicidin Antimicrobial Peptide (CAMP))

Alternative Name: CAP-18

Background: Antimicrobial peptides (AMP) are effector molecules of the innate immune system with direct antimicrobioal and immunomodulatory effects. AMP are produced by epithelial and professional host defense cells such as macrophages or neutrophils. AMP directly inactivate microorganisms and, in addition, have diverse activities on various cell types. In mammals, peptides of the defensin and the cathelicidin families are found. hCAP-18 is the only cathelicidin present in humans. hCAP-18 is a 170 amino acid cathelicidin anti-microbial precursor protein that is proteolytically processed to yield the antibacterial peptide LL-37. The precursor hCAP-18 is found in the specific granules of neutrophils and is expressed in many immune and epithelial cells. Cathelicidin has an established role in host defense. In addition to their direct antimicrobial function, cathelicidin peptides are involved in the modulation of repair and tissue homeostasis, epithelial wound healing, chemoattraction of immune cells, and release of inflammatory mediators from epithelial cells. Recent studies also found that LL-37 significantly regulates endocytic capacity, modifies expression of phagocytic receptors, increases secretion of Th1-inducing cytokines of dendritic cells (DC) generated from blood monocytes, and modulates the response of monocytes and DC to toll like receptor (TLR)-ligands. Moreover LL-37 also modulates the response of neutrophils to bacterial activation.

Pathways: Cellular Response to Molecule of Bacterial Origin